agenT-797 for Stem Cell Transplantation

This trial tests a treatment called agenT-797 to determine its safety for individuals who have undergone a stem cell transplant. The primary goal is to identify any side effects or medical issues that might result from taking agenT-797. Participants will receive this treatment approximately one week after their transplant. It suits adults undergoing a stem cell transplant for certain blood cancers, such as acute myeloid leukemia or myelodysplastic syndrome, using a donor. As a Phase 1 trial, the research aims to understand how the treatment works in people, providing participants the opportunity to be among the first to receive this new treatment.

Research has shown that agenT-797, a type of cell therapy, was safe in earlier studies. Most patients did not experience serious side effects. Notably, no cases of severe immune reactions or donor cells attacking the patient's body occurred. This suggests that agenT-797 could be a safe option for individuals undergoing stem cell transplants.¹²³⁴⁵

Unlike the standard of care for stem cell transplantation, which often involves conventional chemotherapy or radiation to prepare patients for a transplant, agenT-797 is unique because it uses allogeneic invariant natural killer T (iNKT) cells. These iNKT cells are a type of immune cell that can be administered through intravenous infusion, potentially offering a novel way to enhance the body's immune response against cancer cells. Researchers are excited about agenT-797 because it represents a new mechanism of action, targeting cancer cells more directly and possibly with fewer side effects compared to traditional treatments. This approach could lead to better outcomes for patients undergoing stem cell transplantation.

Studies have shown that agenT-797, a type of cell therapy, may help strengthen the immune system. Research suggests it can combat harmful germs and activate the body's defenses. Other trials have found it well-tolerated, indicating safety so far. In patients with various conditions, agenT-797 has shown potential in reducing cancer cells and improving immune health. These early findings offer hope for its benefits in people receiving stem cell transplants. Participants in this trial will receive agenT-797 through a 3+3 dose escalation, administered by intravenous infusion every 2 weeks.⁶⁷⁸⁹¹⁰